Ryu MH - Search Results

1

Biomarker and pharmacodynamic activity of the transforming growth factor-beta (TGFβ) inhibitor SAR439459 as monotherapy and in combination with cemiplimab in a phase I clinical study in patients with advanced solid tumors.

Robbrecht D, Grob JJ, Bechter O, Simonelli M, Doger B, Borbath I, Butler MO, Cheng T, Romano PM, Pons-Tostivint E, Di Nicola M, Curigliano G, Ryu MH, Rodriguez-Vida A, Schadendorf D, Garralda E, Abbadessa G, Demers B, Amrate A, Wang H, Lee JS, Pomponio R, Wang R. Robbrecht D, et al. Among authors: ryu mh. Clin Transl Sci. 2024 Feb;17(2):e13736. doi: 10.1111/cts.13736. Clin Transl Sci. 2024. PMID: 38362837 Free PMC article. Clinical Trial.

2

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial.

Shitara K, Özgüroğlu M, Bang YJ, Di Bartolomeo M, Mandalà M, Ryu MH, Fornaro L, Olesiński T, Caglevic C, Chung HC, Muro K, Goekkurt E, Mansoor W, McDermott RS, Shacham-Shmueli E, Chen X, Mayo C, Kang SP, Ohtsu A, Fuchs CS; KEYNOTE-061 investigators. Shitara K, et al. Among authors: ryu mh. Lancet. 2018 Jul 14;392(10142):123-133. doi: 10.1016/S0140-6736(18)31257-1. Epub 2018 Jun 4. Lancet. 2018. PMID: 29880231 Clinical Trial.

3

Factors associated with the efficacy of first-line nivolumab plus chemotherapy in advanced gastric cancer patients with deficient mismatch repair.

Park YG, Kim HD, Hyung J, Park YS, Ryu MH. Park YG, et al. Among authors: ryu mh. Gastric Cancer. 2024 May 23. doi: 10.1007/s10120-024-01509-2. Online ahead of print. Gastric Cancer. 2024. PMID: 38780852

4

SMARCA4-deficient undifferentiated gastric carcinoma: a case series and literature review.

An HR, Kim HD, Ryu MH, Park YS. An HR, et al. Among authors: ryu mh. Gastric Cancer. 2024 May 22. doi: 10.1007/s10120-024-01510-9. Online ahead of print. Gastric Cancer. 2024. PMID: 38772975

5

Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial.

Shitara K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D, Chung HC, Kawakami H, Yabusaki H, Sakamoto Y, Nishina T, Inaki K, Kuwahara Y, Wada N, Suto F, Arita T, Sugihara M, Tsuchihashi Z, Saito K, Kojima A, Yamaguchi K. Shitara K, et al. Among authors: ryu mh. Nat Med. 2024 May 14. doi: 10.1038/s41591-024-02992-x. Online ahead of print. Nat Med. 2024. PMID: 38745009

6

Clinical and Biomarker Analysis of a Phase I/II Study of PDR001 plus Imatinib for Advanced Treatment-refractory Gastrointestinal Stromal Tumors.

Kim HD, Ryu MH, Park YS, Yoo C, Kim SJ, Kang YK. Kim HD, et al. Among authors: ryu mh. Clin Cancer Res. 2024 Apr 25. doi: 10.1158/1078-0432.CCR-23-4065. Online ahead of print. Clin Cancer Res. 2024. PMID: 38662455

7

Discordant PD-L1 results between 28-8 and 22C3 assays are associated with outcomes of gastric cancer patients treated with nivolumab plus chemotherapy.

Kim HD, Shin J, Song IH, Hyung J, Lee H, Ryu MH, Park YS. Kim HD, et al. Among authors: ryu mh. Gastric Cancer. 2024 Apr 22. doi: 10.1007/s10120-024-01500-x. Online ahead of print. Gastric Cancer. 2024. PMID: 38647978

8

Retrospective analysis on prognosis of oral cancer patients according to surgical approaches for effective cancer ablation: swing approach versus visor approach.

Kim YH, Yang JY, Lee DM, Lee JY, Hwang DS, Ryu MH, Kim UK. Kim YH, et al. Among authors: ryu mh. Maxillofac Plast Reconstr Surg. 2024 Apr 22;46(1):15. doi: 10.1186/s40902-024-00426-9. Maxillofac Plast Reconstr Surg. 2024. PMID: 38647815 Free PMC article.

9

Application of the ERS/ATS Spirometry Standards and Race-Neutral Equations in the COPDGene Study.

Schiavi E, Ryu MH, Martini L, Balasubramanian A, McCormack MC, Fortis S, Regan EA, Bonini M, Hersh CP. Schiavi E, et al. Among authors: ryu mh. Am J Respir Crit Care Med. 2024 Apr 12. doi: 10.1164/rccm.202311-2145OC. Online ahead of print. Am J Respir Crit Care Med. 2024. PMID: 38607551

10

Letter to the editor: 5-year follow-up results of a JCOG1104 (OPAS-1) phase III non-inferiority trial to compare 4 courses and 8 courses of S-1 adjuvant chemotherapy for pathological stage II gastric cancer.

Kim HD, Ryu MH, Lee JS, Kang YK. Kim HD, et al. Among authors: ryu mh. Gastric Cancer. 2024 Apr 11. doi: 10.1007/s10120-024-01496-4. Online ahead of print. Gastric Cancer. 2024. PMID: 38602609 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

403 results

Search Page